Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Receivables: 2024

Historic Receivables for Day One Biopharmaceuticals (DAWN) over the last 1 years, with Dec 2024 value amounting to $13.9 million.

  • Day One Biopharmaceuticals' Receivables rose 92.03% to $16.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.3 million, marking a year-over-year change of. This contributed to the annual value of $13.9 million for FY2024, which is N/A change from last year.
  • Per Day One Biopharmaceuticals' latest filing, its Receivables stood at $13.9 million for FY2024.
  • Day One Biopharmaceuticals' Receivables' 5-year high stood at $13.9 million during FY2024, with a 5-year trough of $13.9 million in FY2024.
  • In the last 1 years, Day One Biopharmaceuticals' Receivables had a median value of $13.9 million in 2024 and averaged $13.9 million.